Advancing Access to High-Quality, Biomarker-Guided Care for All Patients With mNSCLC

Program Description

Biomarker-guided therapy has become a cornerstone of metastatic non-small cell lung cancer (mNSCLC) management, enabling personalized treatment decisions that improve patient outcomes while minimizing unnecessary toxicity. Despite these advances, many patients continue to experience delays in or lack access to comprehensive biomarker testing due to a combination of health system inefficiencies, operational barriers, and patient-specific challenges. These gaps can delay treatment initiation, limit access to appropriate targeted therapies, and contribute to disparities in care. This module examines the systemic and patient-level factors that influence timely biomarker testing and access to precision therapies in mNSCLC. Expert faculty will discuss evidence-based strategies to address barriers across the diagnostic and treatment pathway, including improving multidisciplinary coordination, optimizing testing workflows, enhancing patient navigation and support services, and promoting equitable access to biomarker-driven care. The program also highlights the critical role of oncology pharmacists in identifying barriers, facilitating timely testing, supporting patients throughout the treatment journey, and advancing the delivery of personalized cancer care.

Target audience

Oncology Pharmacists, Nurses, Physicians

Type of activity: Application
Release date: July 31, 2026
Expiration date: July 31, 2027
Learner level: Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Recognize key gaps and variation in access to systemic therapy and biomarker testing for patients with metastatic non–small cell lung cancer (mNSCLC).
• Assess patients for barriers and gaps in access/care that may influence treatment selection, initiation, and outcomes.
• Apply strategies to support delivery of biomarker-guided care to all patients, including multidisciplinary coordination, patient navigation, and system-level interventions.

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.

Faculty

Narjust Florez, MD, FASCO, has the following relevant financial relationships with ineligible companies to disclose: Advisor, Consultant, Fee for Service Recipient: AstraZeneca, Bristol Myers Squibb, Caris Life Sciences, Catalyst Pharmaceuticals, Daiichi Sankyo, EMD Serono, Genentech, Jazz Pharmaceuticals, Johnson & Johnson, Lilly, Merck, Mirati Therapeutics, Novartis, Nuvalent, Nuvation Bio, Pfizer, Regeneron, Sanofi, Takeda Pharmaceuticals

Speakers Bureau: ASCO Post, Clinical Care Options, CME Outfitters, DAVA Oncology

Grant/Research Funding: American Society of Clinical Oncology, AstraZeneca, Champa Fund for Early Cancer Detection, Daiichi Sankyo, Genentech, GO2 for Lung Cancer, International Association for the Study of Lung Cancer, Johnson & Johnson, LUNGevity Foundation, Pfizer, Women’s Health Access Matters Foundation

Dipesh Uprety, MD, has the following relevant financial relationships with ineligible companies to disclose: Research Consultant: Pfizer

Stock: Daiichi Sankyo Inc, AstraZeneca, Jazz Pharmaceuticals, Sanofi, Nuvation Bio, Eli Lilly, Boehringer Ingelheim, Pfizer

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Darren Luon, PharmD, BCOP

Colton Zwart PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Emily Tyler, MHA, PMP; Susan Pordon; Brianna Winters; and Chloe Taccetta

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

Continuing professional education activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved by the labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms